DNA Stock Overview
Engages in the development, manufacturing, and marketing of patented ultrasound systems in Israel, North America, East Asia, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Dna Group (T.R.) Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₪1.05 |
| 52 Week High | ₪1.19 |
| 52 Week Low | ₪0.59 |
| Beta | -0.13 |
| 1 Month Change | 1.36% |
| 3 Month Change | 24.49% |
| 1 Year Change | 3.97% |
| 3 Year Change | -35.85% |
| 5 Year Change | 63.08% |
| Change since IPO | -96.38% |
Recent News & Updates
Recent updates
Dna Group (T.R.)'s (TLV:DNA) Earnings Are Built On Soft Foundations
Mar 20
Dna Group (T.R.)'s (TLV:DNA) Earnings Might Not Be As Promising As They Seem
Sep 02We Think Dna Group (T.R.) (TLV:DNA) Can Afford To Drive Business Growth
Apr 12Dna Group (T.R.) (TLV:DNA) Is In A Strong Position To Grow Its Business
Jul 07We Think Dna Group (T.R.) (TLV:DNA) Can Easily Afford To Drive Business Growth
Jan 24We're Not Worried About D.N.A Biomedical Solutions' (TLV:DNA) Cash Burn
Oct 07Shareholder Returns
| DNA | IL Electronic | IL Market | |
|---|---|---|---|
| 7D | 13.4% | 5.6% | 2.6% |
| 1Y | 4.0% | 30.2% | 25.9% |
Return vs Industry: DNA underperformed the IL Electronic industry which returned 31.6% over the past year.
Return vs Market: DNA underperformed the IL Market which returned 26.6% over the past year.
Price Volatility
| DNA volatility | |
|---|---|
| DNA Average Weekly Movement | 8.1% |
| Electronic Industry Average Movement | 5.9% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in IL Market | 8.3% |
| 10% least volatile stocks in IL Market | 3.6% |
Stable Share Price: DNA's share price has been volatile over the past 3 months compared to the IL market.
Volatility Over Time: DNA's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of IL stocks.
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | n/a | Erez Navon | n/a |
Dna Group (T.R.) Ltd, together with its subsidiaries, engages in the development, manufacturing, and marketing of patented ultrasound systems in Israel, North America, East Asia, and internationally. It provides systems for diagnosing bone strength and density, as well as for monitoring calcium leakage (osteoporosis) in adults and children. The company offers its products for use by skilled physicians, nurses, and operators in hospitals and clinics, as well as in pharmacies and other places.
Dna Group (T.R.) Ltd Fundamentals Summary
| DNA fundamental statistics | |
|---|---|
| Market cap | ₪128.95m |
| Earnings (TTM) | ₪22.10m |
| Revenue (TTM) | ₪306.00k |
5.8x
P/E Ratio421.4x
P/S RatioIs DNA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DNA income statement (TTM) | |
|---|---|
| Revenue | ₪306.00k |
| Cost of Revenue | ₪0 |
| Gross Profit | ₪306.00k |
| Other Expenses | -₪21.79m |
| Earnings | ₪22.10m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.18 |
| Gross Margin | 100.00% |
| Net Profit Margin | 7,220.91% |
| Debt/Equity Ratio | 0% |
How did DNA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/13 23:10 |
| End of Day Share Price | 2025/04/10 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Dna Group (T.R.) Ltd is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.